Skip to main content
Top
Published in: AIDS and Behavior 5/2024

16-02-2024 | Human Immunodeficiency Virus | Original Paper

Association Between Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Scores and HIV Care Continuum Outcomes in People Newly Diagnosed with HIV in the US South

Authors: Manal Ahmed, Ank E. Nijhawan, Ang Gao, Chul Ahn, Jeremy Y Chow

Published in: AIDS and Behavior | Issue 5/2024

Login to get access

Abstract

Mental illness (MI) and substance use (SU) are highly prevalent among people with HIV (PWH) and impact care outcomes. The Substance Abuse and Mental Illness Symptoms Screener (SAMISS) is a validated screener for MI and SU, but it is unknown how screening results at entry to care correlate with subsequent HIV outcomes. This is a retrospective chart review of individuals newly diagnosed with HIV between 2016 and 2019 in a Southern US, safety-net clinic. Baseline demographics, HIV risk factors, socioeconomic variables, and SAMISS screening scores were collected. Outcomes included retention in care, achieving virologic suppression (VS), and continuous VS. Data analyses included stepwise Cox and logistic multivariate regression modeling. Among the 544 newly diagnosed PWH, mean age was 35, 76% were male, 46% non-Hispanic Black, 40% Hispanic/other. Overall, 35% screened positive for SU and 41% for MI. A positive SU (odds ratio (OR) 0.66, p = 0.04) or MI (OR 0.65, p = 0.03) SAMISS screening was associated with lower retention in care in univariate analysis, but was not statistically significant after adjusting for other variables. Positive SAMISS screening for SU and MI were both associated with reduced continuous VS in univariate and multivariate analyses (SU: adjusted OR (aOR) 0.67, p = 0.05; MI: aOR 0.66, p = 0.03). SAMISS is a useful tool for prospectively identifying individuals at risk for low retention in care and for not achieving sustained VS. Future interventions guided by SAMISS may improve HIV care continuum outcomes.
Literature
2.
go back to reference The White House. National HIV/AIDS Strategy for the United States 2022–2025, 2021. The White House. National HIV/AIDS Strategy for the United States 2022–2025, 2021.
8.
go back to reference Relf MV, Holt WLH, Nyblade L, Ellis Caiola L C. A Review of the State of the Science of HIV and Stigma: Context, Conceptualization, Measurement, Interventions, Gaps, and, Priorities F. J Assoc Nurses AIDS Care. 2021;32(3):392–407. https://doi.org/10.1097/jnc.0000000000000237. [published Online First: Epub Date]|. Relf MV, Holt WLH, Nyblade L, Ellis Caiola L C. A Review of the State of the Science of HIV and Stigma: Context, Conceptualization, Measurement, Interventions, Gaps, and, Priorities F. J Assoc Nurses AIDS Care. 2021;32(3):392–407. https://​doi.​org/​10.​1097/​jnc.​0000000000000237​. [published Online First: Epub Date]|.
14.
go back to reference Algarin AB, Sheehan DM, Varas-Diaz N, et al. Enacted HIV-Related Stigma’s association with anxiety & Depression among people living with HIV (PLWH) in Florida. AIDS Behav. 2021;25(1):93–103. [published Online First: Epub Date]|.CrossRefPubMedPubMedCentral Algarin AB, Sheehan DM, Varas-Diaz N, et al. Enacted HIV-Related Stigma’s association with anxiety & Depression among people living with HIV (PLWH) in Florida. AIDS Behav. 2021;25(1):93–103. [published Online First: Epub Date]|.CrossRefPubMedPubMedCentral
16.
go back to reference Crockett KB, Kalichman SC, Kalichman MO, Cruess DG, Katner HP. Experiences of HIV-related discrimination and consequences for internalised stigma, depression and alcohol use. Psychol Health. 2019;34(7):796–810. [published Online First: Epub Date]|.CrossRefPubMedPubMedCentral Crockett KB, Kalichman SC, Kalichman MO, Cruess DG, Katner HP. Experiences of HIV-related discrimination and consequences for internalised stigma, depression and alcohol use. Psychol Health. 2019;34(7):796–810. [published Online First: Epub Date]|.CrossRefPubMedPubMedCentral
20.
go back to reference Bengtson AM, Pence BW, Mimiaga MJ, Gaynes BN, Moore R, Christopoulos K, et al. Depressive symptoms and Engagement in Human Immunodeficiency Virus Care following antiretroviral therapy initiation. Clin Infect Dis. 2019;68(3):475–81. https://doi.org/10.1093/cid/ciy496. [published Online First: Epub Date]|.CrossRef Bengtson AM, Pence BW, Mimiaga MJ, Gaynes BN, Moore R, Christopoulos K, et al. Depressive symptoms and Engagement in Human Immunodeficiency Virus Care following antiretroviral therapy initiation. Clin Infect Dis. 2019;68(3):475–81. https://​doi.​org/​10.​1093/​cid/​ciy496. [published Online First: Epub Date]|.CrossRef
21.
go back to reference Pence BW, Mills JC, Bengtson AM, Gaynes BN, Breger TL, Cook RL, et al. Association of increased chronicity of Depression with HIV Appointment Attendance, Treatment Failure, and Mortality among HIV-Infected adults in the United States. JAMA Psychiatry. 2018;75(4):379–85. https://doi.org/10.1001/jamapsychiatry.2017.4726. [published Online First: Epub Date]|.CrossRef Pence BW, Mills JC, Bengtson AM, Gaynes BN, Breger TL, Cook RL, et al. Association of increased chronicity of Depression with HIV Appointment Attendance, Treatment Failure, and Mortality among HIV-Infected adults in the United States. JAMA Psychiatry. 2018;75(4):379–85. https://​doi.​org/​10.​1001/​jamapsychiatry.​2017.​4726. [published Online First: Epub Date]|.CrossRef
24.
go back to reference Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573–80. https://doi.org/10.1016/s0002-9343(03)00093-7. [published Online First: Epub Date]|.CrossRef Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573–80. https://​doi.​org/​10.​1016/​s0002-9343(03)00093-7. [published Online First: Epub Date]|.CrossRef
27.
go back to reference Breuer E, Stoloff K, Myer L, Seedat S, Stein DJ, Joska JA. The validity of the substance abuse and Mental Illness Symptom Screener (SAMISS) in people living with HIV/AIDS in primary HIV care in Cape Town, South Africa. AIDS Behav. 2014;18(6):1133–41. https://doi.org/10.1007/s10461-014-0698. -y[published Online First: Epub Date]|.CrossRef Breuer E, Stoloff K, Myer L, Seedat S, Stein DJ, Joska JA. The validity of the substance abuse and Mental Illness Symptom Screener (SAMISS) in people living with HIV/AIDS in primary HIV care in Cape Town, South Africa. AIDS Behav. 2014;18(6):1133–41. https://​doi.​org/​10.​1007/​s10461-014-0698. -y[published Online First: Epub Date]|.CrossRef
30.
31.
go back to reference Administration HRaS. HIV/AIDS Bureau Performance Measures. 2019. Administration HRaS. HIV/AIDS Bureau Performance Measures. 2019.
33.
go back to reference Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV–United States, 2011. MMWR Morb Mortal Wkly Rep. 2014;63(47):1113–7. Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV–United States, 2011. MMWR Morb Mortal Wkly Rep. 2014;63(47):1113–7.
40.
41.
go back to reference Sohail M, Long DM, Batey DS, Mugavero MJ, Ojesina AI, Levitan EB. Partnership status and time to viral suppression and sustained viral suppression among newly diagnosed heterosexual people with HIV. Int J STD AIDS. 2022;33(4):347–54. https://doi.org/10.1177/09564624211065227. [published Online First: Epub Date]|.CrossRef Sohail M, Long DM, Batey DS, Mugavero MJ, Ojesina AI, Levitan EB. Partnership status and time to viral suppression and sustained viral suppression among newly diagnosed heterosexual people with HIV. Int J STD AIDS. 2022;33(4):347–54. https://​doi.​org/​10.​1177/​0956462421106522​7. [published Online First: Epub Date]|.CrossRef
50.
go back to reference Centers for Disease Control and Prevention. HIV Surveillance Report. 2019;32. Centers for Disease Control and Prevention. HIV Surveillance Report. 2019;32.
51.
go back to reference Centers for Disease Control and Prevention. NCHHSTP AtlasPlus. Centers for Disease Control and Prevention. NCHHSTP AtlasPlus.
55.
go back to reference Arnold EA, Rebchook GM, Kegeles SM. Triply cursed’: racism, homophobia and HIV-related stigma are barriers to regular HIV testing, treatment adherence and disclosure among young Black Gay Men. Cult Health Sex. 2014;16(6):710–22. [published Online First: Epub Date]|.CrossRefPubMedPubMedCentral Arnold EA, Rebchook GM, Kegeles SM. Triply cursed’: racism, homophobia and HIV-related stigma are barriers to regular HIV testing, treatment adherence and disclosure among young Black Gay Men. Cult Health Sex. 2014;16(6):710–22. [published Online First: Epub Date]|.CrossRefPubMedPubMedCentral
Metadata
Title
Association Between Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Scores and HIV Care Continuum Outcomes in People Newly Diagnosed with HIV in the US South
Authors
Manal Ahmed
Ank E. Nijhawan
Ang Gao
Chul Ahn
Jeremy Y Chow
Publication date
16-02-2024
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2024
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-024-04287-1

Other articles of this Issue 5/2024

AIDS and Behavior 5/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine